ArticleJournal of bioenergetics and biomembranes2026
DNA hypermethylation drives BVES-mediated autophagy to promote cisplatin resistance in lung adenocarcinoma.
Article in Journal of bioenergetics and biomembranes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aberrant DNA methylation induces abnormal expression of drug-resistance genes, promoting drug resistance. This study identified specific DNA methylation patterns driving LUAD chemoresistance and explored their mechanisms. Blood vessel epicardial substance (BVES) expression and methylation were analyzed by using TCGA and MethylMix. Primers for the BVES CpG island were designed with MethPrimer. Pathways for BVES were analyzed by gene set enrichment analysis. Methylation-specific quantitative PCR detected the levels of BVES methylation. Quantitative reverse transcription polymerase chain reaction evaluated BVES expression, and western blot analyzed the expression of BVES, LC3, and P62. The cell counting kit-8 was used to determine IC50 and cell viability. Cell proliferation assessment was achieved by colony formation assay, and apoptosis was evaluated by flow cytometry. LC3 expression was observed through immunofluorescence. The findings displayed hypermethylation of BVES in LUAD tissues and cells, which was further elevated in the setting of cisplatin (DDP) resistance. The overexpression of BVES in A549/DDP cells substantially repressed their proliferation in response to DDP and markedly amplified the apoptotic effects induced by DDP. In the rescue experiments, autophagy stimulants effectively eliminated the DDP sensitivity enhancement caused by BVES overexpression in A549/DDP cells. In vivo assays confirmed that BVES overexpression suppressed autophagy and augmented the therapeutic impact of DDP. BVES hypermethylation, through the promotion of autophagy, reinforces resistance to DDP in LUAD. This study indicates that repressing BVES methylation and upregulating its expression may be a strategic way to combat cisplatin resistance in LUAD patients.
Indexed as
Identifiers
41984391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.